Bispecific Antibody & Bispecific ADC Brochure

High-throughput & Large-Scale Bispecific Antibody & Bispecific ADC Development:

• Multiple Epitopes
• Numerous Target Combination & Backbones
• High-throughput In Vivo Screening

Platform highlights:

• High-throughput and rapid generation of BsADCs

• Huge potential for a large number of BsADCs targeting dual TAAs

• Improved translational efficiency through preclinical testing in large animals

• Target knock-out in RenLite mice increases the chance of obtaining novel binding epitopes and species cross- reactivity, resulting in more diverse products

• Conjugation of payload to naturally available amino acid side-chains (cysteine) is similar to mAbs.